000180373712/312025Q3falsehttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberhttp://fasb.org/us-gaap/2025#ServiceMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesehab:stateehab:segmentehab:entityxbrli:pureehab:location00018037372025-01-012025-09-3000018037372025-11-0300018037372024-01-012024-09-3000018037372024-07-012024-09-3000018037372025-07-012025-09-3000018037372025-09-3000018037372024-12-310001803737us-gaap:CommonStockMember2025-06-300001803737us-gaap:AdditionalPaidInCapitalMember2025-06-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-06-300001803737us-gaap:RetainedEarningsMember2025-06-300001803737us-gaap:TreasuryStockCommonMember2025-06-300001803737us-gaap:NoncontrollingInterestMember2025-06-3000018037372025-06-300001803737us-gaap:RetainedEarningsMember2025-07-012025-09-300001803737us-gaap:NoncontrollingInterestMember2025-07-012025-09-300001803737us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001803737us-gaap:TreasuryStockCommonMember2025-07-012025-09-300001803737us-gaap:CommonStockMember2025-09-300001803737us-gaap:AdditionalPaidInCapitalMember2025-09-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-09-300001803737us-gaap:RetainedEarningsMember2025-09-300001803737us-gaap:TreasuryStockCommonMember2025-09-300001803737us-gaap:NoncontrollingInterestMember2025-09-300001803737us-gaap:CommonStockMember2024-06-300001803737us-gaap:AdditionalPaidInCapitalMember2024-06-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300001803737us-gaap:RetainedEarningsMember2024-06-300001803737us-gaap:TreasuryStockCommonMember2024-06-300001803737us-gaap:NoncontrollingInterestMember2024-06-3000018037372024-06-300001803737us-gaap:RetainedEarningsMember2024-07-012024-09-300001803737us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300001803737us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001803737us-gaap:CommonStockMember2024-07-012024-09-300001803737us-gaap:CommonStockMember2024-09-300001803737us-gaap:AdditionalPaidInCapitalMember2024-09-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300001803737us-gaap:RetainedEarningsMember2024-09-300001803737us-gaap:TreasuryStockCommonMember2024-09-300001803737us-gaap:NoncontrollingInterestMember2024-09-3000018037372024-09-300001803737us-gaap:CommonStockMember2024-12-310001803737us-gaap:AdditionalPaidInCapitalMember2024-12-310001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310001803737us-gaap:RetainedEarningsMember2024-12-310001803737us-gaap:TreasuryStockCommonMember2024-12-310001803737us-gaap:NoncontrollingInterestMember2024-12-310001803737us-gaap:RetainedEarningsMember2025-01-012025-09-300001803737us-gaap:NoncontrollingInterestMember2025-01-012025-09-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-09-300001803737us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001803737us-gaap:CommonStockMember2025-01-012025-09-300001803737us-gaap:TreasuryStockCommonMember2025-01-012025-09-300001803737us-gaap:CommonStockMember2023-12-310001803737us-gaap:AdditionalPaidInCapitalMember2023-12-310001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001803737us-gaap:RetainedEarningsMember2023-12-310001803737us-gaap:TreasuryStockCommonMember2023-12-310001803737us-gaap:NoncontrollingInterestMember2023-12-3100018037372023-12-310001803737us-gaap:RetainedEarningsMember2024-01-012024-09-300001803737us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001803737us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-09-300001803737us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001803737us-gaap:CommonStockMember2024-01-012024-09-300001803737us-gaap:TreasuryStockCommonMember2024-01-012024-09-3000018037372022-07-010001803737ehab:ThirdPartyPayorMedicareMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorOtherMember2025-07-012025-09-300001803737ehab:ThirdPartyPayorOtherMember2024-07-012024-09-300001803737ehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:HospiceSegmentMember2025-07-012025-09-300001803737ehab:HospiceSegmentMember2024-07-012024-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareMemberehab:HospiceSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicareMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMemberehab:HospiceSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicareAdvantageMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMemberehab:HospiceSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorManagedCareMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorManagedCareMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMemberehab:HospiceSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorMedicaidMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorMedicaidMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorOtherMemberehab:HospiceSegmentMember2024-01-012024-09-300001803737ehab:ThirdPartyPayorOtherMember2025-01-012025-09-300001803737ehab:ThirdPartyPayorOtherMember2024-01-012024-09-300001803737ehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:HospiceSegmentMember2025-01-012025-09-300001803737ehab:HospiceSegmentMember2024-01-012024-09-300001803737us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001803737us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001803737ehab:RestrictedStockPerformanceUnitsAndRestrictedStockUnitsRSUsMember2025-07-012025-09-300001803737ehab:RestrictedStockPerformanceUnitsAndRestrictedStockUnitsRSUsMember2025-01-012025-09-300001803737us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001803737us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001803737ehab:RestrictedStockPerformanceUnitsAndRestrictedStockUnitsRSUsMember2024-07-012024-09-300001803737ehab:RestrictedStockPerformanceUnitsAndRestrictedStockUnitsRSUsMember2024-01-012024-09-300001803737us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-09-300001803737us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001803737srt:MinimumMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-01-012025-09-300001803737srt:MaximumMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-01-012025-09-300001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:RevolvingCreditFacilityMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:RevolvingCreditFacilityMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-300001803737us-gaap:RevolvingCreditFacilityMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-300001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-302022-06-300001803737us-gaap:RevolvingCreditFacilityMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-302022-06-300001803737ehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-302022-06-300001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-012022-06-300001803737us-gaap:LetterOfCreditMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-300001803737us-gaap:SecuredDebtMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2023-06-270001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodOneMemberehab:EnhabitCreditAgreementMemberehab:CreditAgreementMember2023-06-272023-06-270001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodTwoMemberehab:EnhabitCreditAgreementMemberehab:CreditAgreementMember2023-06-272023-06-270001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodThreeMemberehab:EnhabitCreditAgreementMemberehab:CreditAgreementMember2023-06-272023-06-270001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodThereafterMemberehab:EnhabitCreditAgreementMemberehab:CreditAgreementMember2023-06-272023-06-270001803737us-gaap:RevolvingCreditFacilityMemberehab:WellsFargoBankNationalAssociationMemberehab:LimitedWaiverMembersrt:MaximumMember2023-09-290001803737us-gaap:RevolvingCreditFacilityMemberehab:WellsFargoBankNationalAssociationMemberehab:LimitedWaiverMembersrt:MinimumMember2023-09-290001803737us-gaap:SecuredDebtMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-030001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodOneMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-032023-11-030001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodTwoMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-032023-11-030001803737us-gaap:SecuredDebtMemberehab:DebtInstrumentCovenantPeriodThereafterMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-032023-11-030001803737us-gaap:SecuredDebtMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-032023-11-030001803737us-gaap:RevolvingCreditFacilityMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-022023-11-020001803737us-gaap:RevolvingCreditFacilityMemberehab:SecondAmendmentMemberehab:CreditAgreementMember2023-11-032023-11-030001803737us-gaap:SecuredDebtMemberehab:TheFirstAmendmentMemberehab:CreditAgreementMember2025-05-090001803737ehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:InterestRateSwapMember2022-10-200001803737us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:RevolvingCreditFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:RevolvingCreditFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2025-09-300001803737us-gaap:RevolvingCreditFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:RevolvingCreditFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:EnhabitCreditAgreementMemberus-gaap:LineOfCreditMember2024-12-310001803737us-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:FinanceLeaseObligationsMember2025-09-300001803737us-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:FinanceLeaseObligationsMember2025-09-300001803737us-gaap:CarryingReportedAmountFairValueDisclosureMemberehab:FinanceLeaseObligationsMember2024-12-310001803737us-gaap:EstimateOfFairValueFairValueDisclosureMemberehab:FinanceLeaseObligationsMember2024-12-310001803737ehab:PriorYearMember2024-09-300001803737us-gaap:InterestRateSwapMember2022-10-310001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-06-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-06-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-310001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-310001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-07-012025-09-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-07-012024-09-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-01-012025-09-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-01-012024-09-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-09-300001803737us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-09-300001803737us-gaap:InterestRateSwapMember2025-09-300001803737us-gaap:InterestRateSwapMember2024-12-310001803737ehab:HomeHealthSegmentMember2025-09-300001803737srt:MinimumMemberehab:HomeHealthSegmentMember2025-09-300001803737srt:MaximumMemberehab:HomeHealthSegmentMember2025-09-300001803737ehab:HospiceSegmentMember2025-09-300001803737srt:MinimumMemberehab:HospiceSegmentMember2025-09-300001803737srt:MaximumMemberehab:HospiceSegmentMember2025-09-300001803737us-gaap:OperatingSegmentsMember2025-07-012025-09-300001803737us-gaap:OperatingSegmentsMember2024-07-012024-09-300001803737us-gaap:OperatingSegmentsMember2025-01-012025-09-300001803737us-gaap:OperatingSegmentsMember2024-01-012024-09-300001803737us-gaap:CorporateNonSegmentMember2025-07-012025-09-300001803737us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001803737us-gaap:CorporateNonSegmentMember2025-01-012025-09-300001803737us-gaap:CorporateNonSegmentMember2024-01-012024-09-300001803737us-gaap:MaterialReconcilingItemsMember2025-07-012025-09-300001803737us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300001803737us-gaap:MaterialReconcilingItemsMember2025-01-012025-09-300001803737us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300001803737ehab:MedicareMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:MedicareMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:MedicareMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:MedicareMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:NonMedicareMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:NonMedicareMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:NonMedicareMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:NonMedicareMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:OtherServiceLineMemberehab:HomeHealthSegmentMember2025-07-012025-09-300001803737ehab:OtherServiceLineMemberehab:HomeHealthSegmentMember2024-07-012024-09-300001803737ehab:OtherServiceLineMemberehab:HomeHealthSegmentMember2025-01-012025-09-300001803737ehab:OtherServiceLineMemberehab:HomeHealthSegmentMember2024-01-012024-09-300001803737ehab:MedalogixLLCMember2019-01-012019-12-310001803737ehab:MedalogixLLCMemberus-gaap:RelatedPartyMember2025-03-192025-03-1900018037372025-03-312025-03-310001803737ehab:MedalogixAnalyticsPlatformsMemberus-gaap:RelatedPartyMember2025-01-012025-09-300001803737ehab:MedalogixAnalyticsPlatformsMemberus-gaap:RelatedPartyMember2024-07-012024-09-300001803737ehab:MedalogixAnalyticsPlatformsMemberus-gaap:RelatedPartyMember2024-01-012024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission file number: 001-41406

___________________

Enhabit, Inc.

(Exact name of registrant as specified in its charter)


Delaware			47-2409192
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

6688 N. Central Expressway, Suite 1300, Dallas, Texas			75206
(Address of principal executive offices)			(Zip Code)

(214) 239-6500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EHAB	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ☒

As of November 3, 2025, the registrant had 50,607,075 shares of its common stock, par value $0.01 per share, outstanding.

ENHABIT, INC.

FORM 10-Q

TABLE OF CONTENTS

Page

Cautionary Note Regarding Forward-Looking Statements

Part I

Financial Information

Item 1

Financial Statements (Unaudited)

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3

Quantitative and Qualitative Disclosures About Market Risk

Item 4

Controls and Procedures

Unregistered Sales of Equity Securities and Use of Proceeds

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this report, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors’, payers’, and other contract counterparties’ information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Our Annual Report on Form 10-K for the year ended December 31, 2024 dated March 6, 2025, which can be found on the Company’s website at http://investors.ehab.com, discusses these and other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this report.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

ENHABIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions, except per share data)	2025		2024		2025		2024
Net service revenue	$	263.6	$	253.6	$	789.6	$	776.6
Cost of service, excluding depreciation and amortization	135.8		131.7		401.5		397.7

General and administrative expenses	105.5		103.8		321.2		321.3
Depreciation and amortization	5.5		8.2		17.5		23.6
Impairment of goodwill	—		107.9		—		107.9
Operating income (loss)	16.8		(98.0)		49.4		(73.9)
Interest expense and amortization of debt discounts and fees	8.3		10.8		26.4		32.8

Other (income) expenses	0.1		—		(19.2)		—
Income (loss) before income taxes and noncontrolling interests	8.4		(108.8)		42.2		(106.7)
(Benefit from) provision for income taxes	(3.2)		0.7		6.5		1.5
Net income (loss)	11.6		(109.5)		35.7		(108.2)
Less: Net income attributable to noncontrolling interests	0.5		0.7		1.6		2.0
Net income (loss) attributable to Enhabit, Inc.	$	11.1	$	(110.2)	$	34.1	$	(110.2)

Weighted average common shares outstanding:
Basic	50.7		50.2		50.8		50.2
Diluted	51.1		50.2		51.2		50.2

Earnings (loss) per common share:
Basic earnings (loss) per share attributable to Enhabit, Inc. common stockholders	$	0.22	$	(2.20)	$	0.67	$	(2.20)
Diluted earnings (loss) per share attributable to Enhabit, Inc. common stockholders	$	0.22	$	(2.20)	$	0.67	$	(2.20)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
Net income (loss)	$	11.6	$	(109.5)	$	35.7	$	(108.2)
Other comprehensive income (loss):
Unrealized gain (loss) on cash flow hedges, net of tax expense of $—, $(0.5), $0.1, and $(0.1) respectively	—		(1.8)		0.2		(0.4)
Total other comprehensive income (loss)	—		(1.8)		0.2		(0.4)
Comprehensive income (loss) including noncontrolling interests	11.6		(111.3)		35.9		(108.6)
Less: Comprehensive income attributable to noncontrolling interests	0.5		0.7		1.6		2.0
Comprehensive income (loss) attributable to Enhabit, Inc.	$	11.1	$	(112.0)	$	34.3	$	(110.6)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)


(in millions)	September 30, 2025		December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	56.9	$	28.4
Restricted cash	2.0		1.9
Accounts receivable, net of allowances	148.7		149.2




Prepaid expenses and other current assets	6.1		13.2
Total current assets	213.7		192.7
Property and equipment, net	16.1		17.7
Operating lease right-of-use assets	50.8		52.8
Goodwill	900.0		900.0
Intangible assets, net	45.2		58.1
Other long-term assets	2.5		4.7
Total assets	$	1,228.3	$	1,226.0
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	22.3	$	22.8
Current operating lease liabilities	12.9		12.3
Accounts payable	7.2		6.7
Accrued payroll	49.3		37.1






Other current liabilities	43.8		47.3
Total current liabilities	135.5		126.2
Long-term debt, net of current portion	441.5		492.6
Long-term operating lease liabilities, net of current portion	39.8		41.8
Deferred income tax liabilities	14.2		11.5

Total liabilities	631.0		672.1
Commitments and contingencies (See Note 6)
Redeemable noncontrolling interests	5.0		5.0
Stockholders’ equity:






Total Enhabit, Inc. stockholders’ equity	566.8		523.5
Noncontrolling interests	25.5		25.4
Total stockholders’ equity	592.3		548.9
Total liabilities and stockholders’ equity	$	1,228.3	$	1,226.0

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(UNAUDITED)


	Three Months Ended September 30, 2025
	Enhabit, Inc. Common Stockholders
	Common Stock			Capital in Excess of Par Value		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Treasury Stock			Noncontrolling Interests		Total
(in millions)	Shares	Amount								Shares	Amount
Balance at June 30, 2025	50.6	$	0.5	$	433.6	$	—	$	121.3	0.4	$	(3.0)	$	25.5	$	577.9
Net income	—	—		—		—		11.1		—	—		0.5		11.6



Distributions	—	—		—		—		—		—	—		(0.5)		(0.5)



Stock-based compensation expense	—	—		3.6		—		—		—	—		—		3.6
Shares forfeited, including forfeitures due to net share settlement of income taxes	—	—		—		—		—		—	(0.3)		—		(0.3)

Balance at September 30, 2025	50.6	$	0.5	$	437.2	$	—	$	132.4	0.4	$	(3.3)	$	25.5	$	592.3

	Three Months Ended September 30, 2024
	Enhabit, Inc. Common Stockholders
	Common Stock			Capital in Excess of Par Value		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Treasury Stock			Noncontrolling Interests		Total
(in millions)	Shares	Amount								Shares	Amount
Balance at June 30, 2024	50.2	$	0.5	$	419.8	$	0.9	$	254.5	0.2	$	(1.4)	$	26.1	$	700.4
Net (loss) income	—	—		—		—		(110.2)		—	—		0.7		(109.5)
Other comprehensive loss, net of tax	—	—		—		(1.8)		—		—	—		—		(1.8)





Stock-based compensation expense	—	—		3.8		—		—		—	—		—		3.8

Issuance of common stock pursuant to omnibus incentive plan	0.1	—		—		—		—		—	—		—		—
Balance at September 30, 2024	50.3	$	0.5	$	423.6	$	(0.9)	$	144.3	0.2	$	(1.4)	$	26.8	$	592.9

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)


	Nine Months Ended September 30, 2025
	Enhabit, Inc. Common Stockholders
	Common Stock			Capital in Excess of Par Value		Other Comprehensive Income (Loss)		Retained Earnings		Treasury Stock			Noncontrolling Interests		Total
(in millions)	Shares	Amount								Shares	Amount
Balance at December 31, 2024	50.4	$	0.5	$	426.6	$	(0.2)	$	98.3	0.2	$	(1.7)	$	25.4	$	548.9
Net income	—	—		—		—		34.1		—	—		1.6		35.7
Other comprehensive income, net of tax	—	—		—		0.2		—		—	—		—		0.2


Distributions	—	—		—		—		—		—	—		(1.5)		(1.5)

Stock-based compensation expense	—	—		10.6		—		—		—	—		—		10.6
Shares forfeited, including forfeitures due to net share settlement of income taxes	(0.2)	—		—		—		—		0.2	(1.6)		—		(1.6)
Issuance of common stock pursuant to omnibus incentive plan	0.4	—		—		—		—		—	—		—		—
Balance at September 30, 2025	50.6	$	0.5	$	437.2	$	—	$	132.4	0.4	$	(3.3)	$	25.5	$	592.3

	Nine Months Ended September 30, 2024
	Enhabit, Inc. Common Stockholders
	Common Stock			Capital in Excess of Par Value		Other Comprehensive Income (Loss)		Retained Earnings		Treasury Stock			Noncontrolling Interests		Total
(in millions)	Shares	Amount								Shares	Amount
Balance at December 31, 2023	50.1	$	0.5	$	415.8	$	(0.5)	$	254.5	0.1	$	(0.6)	$	27.0	$	696.7
Net (loss) income	—	—		—		—		(110.2)		—	—		2.0		(108.2)
Other comprehensive loss, net of tax	—	—		—		(0.4)		—		—	—		—		(0.4)

Distributions	—	—		—		—		—		—	—		(2.2)		(2.2)


Stock-based compensation expense	—	—		7.8		—		—		—	—		—		7.8
Shares forfeited, including forfeitures due to net share settlement of income taxes	(0.1)	—		—		—		—		0.1	(0.8)		—		(0.8)
Issuance of common stock pursuant to omnibus incentive plan	0.3	—		—		—		—		—	—		—		—
Balance at September 30, 2024	50.3	$	0.5	$	423.6	$	(0.9)	$	144.3	0.2	$	(1.4)	$	26.8	$	592.9

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)


	Nine Months Ended September 30,
(in millions)	2025		2024
Cash flows from operating activities:
Net income (loss)	$	35.7	$	(108.2)
Adjustments to reconcile net income (loss) to net cash provided by operating activities—
Depreciation and amortization	17.5		23.6
Amortization of debt-related costs	1.1		1.1
Gain on sale of investment	(19.3)		—
Impairment of goodwill	—		107.9


Stock-based compensation	9.8		7.8
Deferred income taxes	2.5		0.1
Other	0.3		(0.7)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable, net of allowances	0.5		13.8
Prepaid expenses and other assets	7.7		5.9
Accounts payable	0.5		2.3
Accrued payroll	13.1		8.6
Other liabilities	(3.1)		(6.9)
Net cash provided by operating activities	66.3		55.3
Cash flows from investing activities:

Purchases of property and equipment, including capitalized software costs	(3.8)		(3.2)
Proceeds from sale of investment	21.0		—
Other	0.4		1.1
Net cash provided by (used in) investing activities	17.6		(2.1)
Cash flows from financing activities:
Principal payments on term loan facility	(15.0)		(15.0)
Payments on revolving credit facility	(35.0)		(15.0)
Principal payments under finance lease obligations	(2.1)		(2.6)

Distributions paid to noncontrolling interests of consolidated affiliates	(1.5)		(2.2)



Other	(1.7)		(0.8)
Net cash used in financing activities	(55.3)		(35.6)
Increase in cash, cash equivalents, and restricted cash	28.6		17.6
Cash, cash equivalents, and restricted cash at beginning of period	30.3		29.8
Cash, cash equivalents, and restricted cash at end of period	$	58.9	$	47.4

See also Note 9, Supplemental Cash Flow Information.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.Summary of Significant Accounting Policies

Organization and Description of Business. Enhabit, Inc. (“Enhabit” or the “Company”), incorporated in Delaware in 2014, provides a comprehensive range of Medicare-certified skilled home health and hospice services in 34 states, with a concentration in the southern half of the United States. The Company manages its operations and discloses financial information using two reportable segments: (i) Home Health and (ii) Hospice. See Note 7, Segment Reporting. Prior to July 1, 2022, the Company operated as a reporting segment of Encompass Health Corporation (“Encompass”).

Separation from Encompass. On July 1, 2022, Encompass completed the separation of the Company through the distribution of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit to the stockholders of record of Encompass (the “Distribution”). As a result of the Distribution, Enhabit is now an independent public company, and its common stock is listed under the symbol “EHAB” on the New York Stock Exchange (the “Separation”).

The Separation was completed pursuant to a separation and distribution agreement (the “Separation and Distribution Agreement”) and other agreements with Encompass related to the Separation, including, but not limited to, a tax matters agreement (the “Tax Matters Agreement”), an employee matters agreement (the “Employee Matters Agreement”), and a transition services agreement (the “Transition Services Agreement” or “TSA”). Following the Separation, certain functions were provided by Encompass under the TSA. Following the expiration of the TSA, these functions are now performed using the Company’s own resources or third‑party providers.

Basis of Presentation and Consolidation. The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries should be read in conjunction with the audited consolidated financial statements and accompanying notes contained in the Company’s Annual Report for the year ended December 31, 2024 on Form 10-K (the “Form 10-K”) filed with the United States Securities and Exchange Commission (the “SEC”) on March 6, 2025. The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the rules and regulations of the SEC applicable to interim financial information. Accordingly, certain information and note disclosures included in financial statements prepared in accordance with GAAP have been omitted in these interim statements, as allowed by such SEC rules and regulations. The unaudited Condensed Consolidated Balance Sheet as of December 31, 2024 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, management believes the disclosures are adequate to make the information presented not misleading.

The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In management’s opinion, the accompanying unaudited condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary for a fair statement of the financial position, results of operations, and cash flows for each interim period presented.

The unaudited condensed consolidated financial statements include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which the Company exercises control, and, when applicable, entities in which the Company has a controlling financial interest. Enhabit eliminates all intercompany accounts and transactions within the Company from its financial results.

Reclassification. Certain prior period balances have been reclassified to conform to the current period presentation in the unaudited condensed consolidated financial statements. The reclassifications did not have any effect on the Company’s financial position, results of operations, or cash flows.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

Net Service Revenue. Net service revenue disaggregated by payer source and segment is as follows (in millions):


	Home Health				Hospice				Consolidated
	Three Months Ended September 30,
	2025		2024		2025		2024		2025		2024
Medicare	$	113.4	$	117.3	$	63.0	$	51.7	$	176.4	$	169.0
Medicare Advantage	61.2		59.2		—		—		61.2		59.2
Managed Care	23.4		22.2		0.1		0.3		23.5		22.5
Medicaid	1.7		2.2		—		0.6		1.7		2.8
Other	0.8		0.1		—		—		0.8		0.1
Total	$	200.5	$	201.0	$	63.1	$	52.6	$	263.6	$	253.6

	Home Health				Hospice				Consolidated
	Nine Months Ended September 30,
	2025		2024		2025		2024		2025		2024
Medicare	$	343.6	$	367.3	$	180.0	$	150.0	$	523.6	$	517.3
Medicare Advantage	185.6		179.8		—		—		185.6		179.8
Managed Care	68.7		68.8		1.8		2.2		70.5		71.0
Medicaid	5.7		7.1		0.7		—		6.4		7.1
Other	3.4		1.4		0.1		—		3.5		1.4
Total	$	607.0	$	624.4	$	182.6	$	152.2	$	789.6	$	776.6

For a discussion of the Company’s significant accounting policies, including its policy related to Net service revenue, see Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements included in the Form 10‑K.

Earnings (Loss) Per Common Share. The following table sets forth the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2025 and 2024 (in millions):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Weighted average common shares outstanding:
Basic	50.7	50.2	50.8	50.2
Dilutive effect of restricted stock, restricted stock units and performance units	0.4	—	0.4	—
Diluted	51.1	50.2	51.2	50.2

A total of 0.3 million options to purchase Enhabit’s shares, for each of the three and nine months ended September 30, 2025, and 0.2 million and 0.3 million shares of restricted stock awards, performance units and restricted stock units, for the three and nine months ended September 30, 2025, respectively, were excluded from the diluted weighted average common shares outstanding because their effects were anti‑dilutive. A total of 0.3 million options to purchase Enhabit’s shares and 2.1 million shares of restricted stock awards, performance units and restricted stock units were excluded from the diluted weighted average common shares outstanding for each of the three and nine months ended September 30, 2024 because their effects were anti-dilutive. See Note 9, Stock-Based Payments, to the consolidated financial statements included in the Form 10-K for additional information.

Accrued Other Expenses. Accrued other expenses includes $9.0 million and $13.5 million of accrued hospice-related costs, $5.3 million and $6.7 million of legal fees, $6.6 million and $6.6 million of workers’ compensation expense and $6.9 million and $5.5 million of medical insurance costs as of September 30, 2025 and December 31, 2024, respectively.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

Recent Accounting Pronouncements. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This standard requires disaggregated income tax disclosures on the effective tax rate reconciliation and income taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted, and the disclosures in this standard are required to be applied on a prospective basis with the option to apply the standard retrospectively. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements, but will require certain additional disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement (Topic 220): Reporting Comprehensive Income—Expense Disaggregation Disclosures.” Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. This standard requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to all prior periods presented in the financial statements. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements, but will require certain additional disclosures.

In May 2025, the FASB issued ASU 2025-03, “Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity.” This standard requires an entity to consider certain additional factors to identify the accounting acquirer for acquired entities that are not variable interest entities (“VIE”) in a business combination. When applying those factors, an entity may determine that a transaction is a reverse acquisition (in which the legal acquirer is identified as the acquiree for accounting purposes) or that the transaction should not be accounted for as a business combination. However, in a business combination in which a VIE is acquired, current guidance requires that the primary beneficiary is always the accounting acquirer. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual periods and is applied on a prospective basis to all business combinations that have an acquisition date that occurs on or after the date of initial application of this ASU. While this ASU does not impact our current VIEs, it could impact the way we evaluate and account for any future business combinations.

In July 2025, the FASB issued ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets.” This standard provides all entities with a practical expedient. The practical expedient allows companies to assume that current conditions as of the balance sheet date do not change for the life of the asset when developing reasonable and supportable forecasts as part of estimating expected credit losses. This ASU is effective for annual reporting period beginning after December 15, 2025, and interim reporting periods within those annual periods and is applied prospectively to estimates of expected credit losses on asset balances. Early adoption is permitted. The Company is currently evaluating the potential impact this standard has on its consolidated financial statements and related disclosures.

2.Variable Interest Entities (“VIEs”)

As of September 30, 2025 and December 31, 2024, Enhabit consolidated two joint venture entities that are VIEs and of which the Company is the primary beneficiary. The Company’s ownership percentages in these entities range from 60% and 90% as of September 30, 2025. Through partnership and management agreements with or governing these entities, Enhabit manages these entities and handles all day-to-day operating decisions. Accordingly, management has the decision‑making power over the activities that most significantly impact the economic performance of the VIEs and the Company has an obligation to absorb losses or receive benefits from the VIEs that could potentially be significant to the VIEs. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing the VIEs prohibit the Company from using the assets of the VIEs to satisfy the obligations of other entities.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in Enhabit’s unaudited Condensed Consolidated Balance Sheets, are as follows (in millions):


	As of September 30, 2025		As of December 31, 2024
Assets
Current assets:
Restricted cash	$	1.6	$	1.4
Accounts receivable, net of allowances	1.7		2.1

Total current assets	3.3		3.5

Operating lease right-of-use assets	—		0.1
Goodwill	12.4		12.4
Intangible assets, net	0.6		0.7
Total assets	$	16.3	$	16.7
Liabilities
Current liabilities:
Current operating lease liabilities	$	—	$	0.1
Accrued payroll	0.3		0.2
Other current liabilities	0.7		0.9
Total current liabilities	1.0		1.2

Other long-term liabilities	—		0.1
Total liabilities	$	1.0	$	1.3

3.Long‑Term Debt

Long-term debt outstanding consists of the following (in millions):


	As of September 30, 2025		As of December 31, 2024
Credit agreement—
Term loan A facility	$	333.5	$	348.0
Advances under revolving credit facility	125.0		160.0

Finance lease obligations	5.3		7.4
Total debt	463.8		515.4
Less: Current portion	(22.3)		(22.8)
Long-term debt, net of current portion	$	441.5	$	492.6

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

The following table shows scheduled principal payments due on Enhabit’s long-term debt for the next five years (in millions):


	Amount
October 1 through December 31, 2025	$	5.6
2026	22.3
2027	437.1
2028 and thereafter	0.3



Gross maturities	465.3
Less: Unamortized debt issuance costs	(1.5)
Total	$	463.8

In June 2022, the Company entered into a credit agreement (the “Credit Agreement”) that consists of a $400.0 million term loan A facility (the “Term Loan A Facility”) and a $350.0 million revolving credit facility (the “Revolving Credit Facility” and together with the Term Loan A Facility, the “Credit Facilities”). The Credit Facilities mature in June 2027. Interest on the loans under the Credit Facilities is calculated by reference to the Secured Overnight Financing Rate (“SOFR”) or an alternative base rate, plus an applicable interest rate margin. Enhabit may voluntarily prepay outstanding loans under the Credit Facilities at any time without premium or penalty, other than customary breakage costs with respect to SOFR loans. The Term Loan A Facility contains customary mandatory prepayments, including with respect to proceeds from asset sales and from certain incurrences of indebtedness.

On June 30, 2022, the Company drew the full $400.0 million of the Term Loan A Facility and $170.0 million on the Revolving Credit Facility. The net proceeds of $566.6 million were distributed to Encompass prior to the completion of the Distribution. For additional information on the Separation, see Item 1, “Business—Our History,” in the Form 10-K.

The Term Loan A Facility amortizes by an amount per annum equal to 5.0% of the outstanding principal amount thereon as of the closing date, payable in equal quarterly installments, with the balance being payable in June 2027. The Revolving Credit Facility provides the ability to borrow and obtain letters of credit, which is subject to a $75.0 million sublimit. Obligations under the Credit Facilities are guaranteed by Enhabit’s existing and future wholly-owned domestic material subsidiaries (the “Guarantors”), subject to certain exceptions. Borrowings under the Credit Facilities are secured by first priority liens on substantially all the assets of Enhabit and the Guarantors, subject to certain exceptions. The Credit Facilities contain representations and warranties, affirmative and negative covenants, and events of default customary for secured financings of this type, including limitations with respect to liens, fundamental changes, indebtedness, restricted payments, investments, and affiliate transactions, in each case, subject to a number of important exceptions and qualifications.

On June 27, 2023, Enhabit amended the Credit Facilities (the “First Amendment”) to provide for, among other things: (i) a new tier to the pricing grid for interest rate margins when the total net leverage ratio (“Total Net Leverage Ratio”, as defined in the Credit Agreement) exceeds 4.50 to 1.00; (ii) changes to the conditions concerning the Company’s Total Net Leverage Ratio that must be met for the Company to borrow incremental ratio-based amounts; (iii) an increase in the maximum permitted Total Net Leverage Ratio to 5.25 to 1.00 for the quarters ended June 30, 2023, September 30, 2023, and December 31, 2023, stepping down to 5.00 to 1.00 for the quarter ended March 31, 2024, 4.75 to 1.00 for the quarter ended June 30, 2024, and 4.50 to 1.00 for the quarter ended September 30, 2024 and thereafter; and (iv) modifications to the Company’s ability to declare and make certain restricted payments.

On September 29, 2023, Enhabit entered into a Limited Waiver (the “Waiver”) with Wells Fargo Bank, National Association, as administrative agent to the other lenders (the “Administrative Agent”) under the Credit Agreement and the First Amendment. The Waiver released the Company from the requirement to comply with the Total Net Leverage Ratio and the interest coverage ratio (“Interest Coverage Ratio”, as defined in the Credit Agreement) covenants for the three months ended September 30, 2023. The Waiver also required that, until such time as the Company certified compliance with the waived financial covenants, the aggregate principal amount of the Company’s revolving loans allowed under the Credit Agreement was decreased from $350.0 million to $230.0 million. All other covenants and terms of the Credit Agreement remained unchanged and in effect. Although the Company was not required to be in compliance with the financial covenants as of September 30, 2023, it was in compliance with the financial covenants under the Credit Facilities.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

As of September 30, 2023, Enhabit’s forecasted results suggested there was uncertainty of meeting the covenants through a period of one year from the issuance date of the September 30, 2023 financial statements. As a result, on November 3, 2023, the Company amended the Credit Facilities (the “Second Amendment”) to provide for, among other things, (i) an increase in the maximum permitted Total Net Leverage Ratio to 6.75 to 1.00 for the quarters ended December 31, 2023 and March 31, 2024, stepping down to 6.50 to 1.00 for the quarters ended June 30, September 30 and December 31, 2024, 5.75 to 1.00 for the quarter ended March 31, 2025, and 4.50 to 1.00 for the quarter ended June 30, 2025 and thereafter; (ii) the addition of a Fixed Charge Coverage Ratio (as defined in the Credit Agreement) covenant of 1.15 to 1.00 until the end of the Covenant Adjustment Period (as defined below); (iii) no Interest Coverage Ratio covenant until the end of the Covenant Adjustment Period; (iv) a permanent reduction in the Revolving Credit Facility commitment from $350.0 million to $220.0 million; (v) an increase in the Applicable Commitment Fee (as defined in the Credit Agreement) during the Covenant Adjustment Period; (vi) suspension of the ability of the Company to request incremental commitments under the Credit Agreement during the Covenant Adjustment Period; (vii) an increase of 0.25% in the applicable interest rate margins on amounts outstanding under the Credit Agreement during the Covenant Adjustment Period; (viii) limits on the amount of cash the Company can keep on hand and outside the lender group during the Covenant Adjustment Period; and (ix) additional limits on permitted indebtedness and acquisitions, permitted liens, restricted payments and permitted investments during the Covenant Adjustment Period. The “Covenant Adjustment Period” begins on the date of the Second Amendment and ends on the earlier of (a) the date that the Company provides evidence of compliance with the financial covenants in the Credit Agreement, as amended, for the fiscal quarter ended June 30, 2025 and (b) the date that the Company provides evidence of compliance with the financial covenants in the Credit Agreement as in effect immediately prior to the First Amendment for the applicable quarter.

As of May 9, 2025, the Covenant Adjustment Period ended and the Company became subject to the financial covenants in the Credit Agreement as required by the First Amendment for each applicable quarter starting with the fiscal quarter ended June 30, 2025. These requirements include, among other things, (i) a maximum permitted Total Net Leverage Ratio of 4.5 to 1.0, and (ii) a minimum Interest Coverage Ratio of no less than 2.5 to 1.0 for the previous four consecutive quarters. The end of the Covenant Adjustment Period also resulted in, among other things, (a) a reset of the Applicable Commitment Fee (as defined in the Credit Agreement) to the levels in place prior the Covenant Adjustment Period; (b) the removal of the suspension of the ability of the Company to request incremental commitments under the Credit Agreement; (c) a reset of the applicable interest rate margins on amounts outstanding under the Credit Agreement to the levels in place prior the Covenant Adjustment Period; (d) the removal of limits imposed on the Company for the amount of cash the Company can keep on hand and outside the lender group; and (e) the removal of additional limits on permitted indebtedness and acquisitions, permitted liens, restricted payments and permitted investments imposed during the Covenant Adjustment Period.

Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, Enhabit may not be able to borrow under the Revolving Credit Facility. Additionally, violation of the covenants would result in an event of default under the Credit Facilities. A default that occurs, and is not cured within any applicable cure period or is not waived, would permit lenders to accelerate the maturity of the debt under the Credit Facilities and to foreclose upon any collateral securing the debt.

As of September 30, 2025, Enhabit was in compliance with the financial covenants under the Credit Facilities. Although Enhabit’s forecasted results indicate the Company will continue to be in compliance with those financial covenants through a period of one year from the issuance date of the September 30, 2025 financial statements, management cannot guarantee continued compliance throughout this period. Management continually evaluates the Company’s expected compliance with the covenants described above and takes all appropriate steps to proactively renegotiate such covenants when appropriate.

As of September 30, 2025, amounts drawn under the Term Loan A Facility and the Revolving Credit Facility had a weighted average interest rate of 6.4%. On October 20, 2022, Enhabit entered into an interest rate swap to manage the Company’s exposure to interest rate movements for a portion of the Term Loan A Facility. The interest rate swap had a $200.0 million notional value and a maturity date of October 20, 2025. Beginning in October 2022, the Company received the one-month SOFR and paid a fixed rate of interest of 4.3%. See also Note 5, Derivative Instrument.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

The carrying amounts and estimated fair values for long-term debt are presented in the following table (in millions):


	As of September 30, 2025				As of December 31, 2024
	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Long-term debt:
Term loan A facility	$	333.5	$	329.9	$	348.0	$	345.3
Advances under revolving credit facility	$	125.0	$	125.0	$	160.0	$	160.0

Finance lease obligations	$	5.3	$	5.3	$	7.4	$	7.4

Fair values for long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies—Fair Value Measurements, to the consolidated financial statements included in the Form 10-K.

4.Income Taxes

The Company’s effective income tax rates were (38.1)% and 15.4% for the three and nine months ended September 30, 2025, respectively. The effective income tax rates differed from the federal statutory rate primarily due to a reduction to the valuation allowance of $4.4 million relating to deferred tax assets originating in a prior year. The reduction in the valuation allowance is primarily attributable to provisions of the One Big Beautiful Bill Act enacted on July 4, 2025.

The Company’s effective income tax rates were (0.6)% and (1.4)% for the three and nine months ended September 30, 2024, respectively. The rates differed from the federal statutory rate primarily due to permanent differences attributable to an impairment of goodwill and a valuation allowance recorded against a portion of the deferred tax assets. In the third quarter of 2024, the Company recorded a valuation allowance of $12.0 million, of which $3.4 million relates to deferred tax assets arising in a prior year.

5.Derivative Instrument

In October 2022, Enhabit entered into an interest rate swap agreement with a notional value of $200.0 million and a maturity of October 20, 2025. See Note 3, Long‑Term Debt.

The activities of the cash flow hedge included in Accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2025 and 2024 are presented in the following table (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Balance at beginning of period	$	—	$	0.9	$	(0.2)	$	(0.5)
Unrealized gain (loss) recognized in other comprehensive income, net of tax	—		(1.4)		0.2		0.7
Reclassified to interest expense, net of tax	—		(0.4)		—		(1.1)
Balance at end of period	$	—	$	(0.9)	$	—	$	(0.9)

The fair value of derivative assets and liabilities within the unaudited Condensed Consolidated Balance Sheets are presented in the following table (in millions):


	As of September 30, 2025		As of December 31, 2024

Other current liabilities	$	—	$	(0.3)

Total	$	—	$	(0.3)

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

The fair value of the Company’s derivative instrument was determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies—Fair Value Measurements, to the consolidated financial statements included in the Form 10-K.

6.Contingencies and Other Commitments

Enhabit operates in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against the Company. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect the Company’s financial position, results of operations, and cash flows in a given period.

There were no claims made against the Company that are probable of loss and reasonably estimable as liabilities within Other current liabilities in the unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 or December 31, 2024.

Other Commitments

Enhabit is a party to service and other contracts in connection with conducting its business. Minimum amounts due under these agreements are $16.0 million in 2025, $19.3 million in 2026, and $10.0 million thereafter. These contracts primarily relate to medical and durable medical equipment used in the two reporting segments, and business and software licensing and support. Certain of these agreements include variable arrangements, such as the cost to the supplier plus a designated mark-up percentage, or a fixed rate per patient count per month in the two reporting segments.

7.Segment Reporting

Enhabit’s two reportable segments, Home Health and Hospice, are based on the major types of services provided by the Company, as described below. The Chief Executive Officer, who is also the Chief Operating Decision Maker, uses these segment groupings and the results of each segment, measured by Segment Adjusted EBITDA, to evaluate performance and allocate resources, primarily during the annual budget process and regular operational performance reviews. Segment assets are not reviewed by the Chief Operating Decision Maker and therefore are not disclosed below.

•Home Health - Enhabit operates home health agencies in 33 states, with a concentration in the southern half of the United States. As of September 30, 2025, the Company operates 247 home health agencies. Enhabit is the sole owner of 236 of these locations. The Company retains 50.0% to 81.0% ownership in the remaining 11 jointly owned locations. Home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services.

•Hospice - Enhabit’s hospice operations represent one of the nation’s largest providers of Medicare-certified hospice services. The Company operates hospice provider locations in 25 states, with a concentration in the southern half of the United States. As of September 30, 2025, the Company operates 115 hospice provider locations. Enhabit is the sole owner of 111 of these locations. The Company retains 50.0% to 90.0% ownership in the remaining four jointly owned locations. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself.

The accounting policies of the reportable segments are the same as those described in Note 1, Summary of Significant Accounting Policies. All revenues for services are generated through external customers. See Note 1, Summary of Significant Accounting Policies—Net Service Revenue, for the disaggregation of revenues. No corporate overhead is allocated to either of the reportable segments. Other cost of service is comprised of third-party services and other individually insignificant costs in the Home Health segment. Other cost of service is comprised of medical director, skilled nursing facilities and other individually insignificant costs in the Hospice segment. Other general and administrative expenses are comprised of licensing fees and other individually insignificant fees for both the Home Health and Hospice segments.

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

Selected financial information for Enhabit’s reportable segments is as follows (in millions):


	Home Health				Hospice
	Three Months Ended September 30,				Three Months Ended September 30,
	2025		2024		2025		2024
Net service revenue	$	200.5	$	201.0	$	63.1	$	52.6

Labor	98.7		96.5		18.4		16.0
Supplies and pharmacy	2.4		2.4		5.6		4.9
Travel	5.1		5.3		1.3		1.2
Other cost of service	1.5		1.7		2.8		3.7
Total cost of service, excluding depreciation and amortization	107.7		105.9		28.1		25.8

General and administrative salaries	46.3		48.0		14.8		13.7
Other general and administrative expenses	12.2		10.2		2.9		2.8
Total general and administrative expenses	58.5		58.2		17.7		16.5


Net income attributable to noncontrolling interests	0.4		0.4		0.1		0.3
Segment Adjusted EBITDA	$	33.9	$	36.5	$	17.2	$	10.0


	Home Health				Hospice
	Nine Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net service revenue	$	607.0	$	624.4	$	182.6	$	152.2

Labor	291.1		293.4		52.8		46.8
Supplies and pharmacy	7.2		7.5		16.2		14.2
Travel	15.4		16.5		3.7		3.5
Other cost of service	4.6		5.3		10.5		10.5
Total cost of service, excluding depreciation and amortization	318.3		322.7		83.2		75.0

General and administrative salaries	139.8		144.4		43.4		40.0
Other general and administrative expenses	36.2		31.9		9.4		8.5
Total general and administrative expenses	176.0		176.3		52.8		48.5


Net income attributable to noncontrolling interests	1.2		1.5		0.4		0.5
Segment Adjusted EBITDA	$	111.5	$	123.9	$	46.2	$	28.2

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

Total segment reconciliations (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Total Segment Adjusted EBITDA	$	51.1	$	46.5	$	157.7	$	152.1
Non-segment general and administrative expenses	(27.1)		(25.3)		(82.6)		(88.7)
Interest expense and amortization of debt discounts and fees	(8.3)		(10.8)		(26.4)		(32.8)
Depreciation and amortization	(5.5)		(8.2)		(17.5)		(23.6)
(Loss) gain on sale of investment	(0.1)		—		19.2		—
Impairment of goodwill	—		(107.9)		—		(107.9)
Stock-based compensation expense	(2.2)		(3.8)		(9.8)		(7.8)
Net income attributable to noncontrolling interests	0.5		0.7		1.6		2.0

Income (loss) before income taxes and noncontrolling interests	$	8.4	$	(108.8)	$	42.2	$	(106.7)

Additional detail regarding the revenues of the operating segments by payer type follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Home Health:
Medicare	$	113.4	$	117.3	$	343.6	$	367.3
Non-Medicare	85.2		81.5		257.4		250.5
Private duty(1)	1.9		2.2		6.0		6.6
Total Home Health	200.5		201.0		607.0		624.4
Hospice	63.1		52.6		182.6		152.2
Total net service revenue	$	263.6	$	253.6	$	789.6	$	776.6

(1) Private duty represents long-term comprehensive hourly nursing medical care.

8.Related Party Transactions

In connection with the Separation, as discussed in Note 1, Summary of Significant Accounting Policies, Enhabit entered into several agreements with Encompass that govern or used to govern the relationship of the parties following the Distribution, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement, and an Employee Matters Agreement. The Separation and Distribution Agreement contains provisions that, among other things, relate to (i) assets, liabilities, and contracts to be transferred, assumed, and assigned to each of Enhabit and Encompass as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of the Enhabit business with Enhabit and financial responsibility for the obligations and liabilities of Encompass’s remaining business with Encompass, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation between Enhabit and Encompass of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Enhabit’s and Encompass’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Enhabit’s business and Encompass’s business.

Transition Services Agreement

Historically, Encompass provided the Company with certain services, including, but not limited to, executive oversight, treasury, legal, accounting, human resources, tax, internal audit, financial reporting, information technology and

Table of Contents

ENHABIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED, CONTINUED)

investor relations. After the Separation, some of these services continued to be provided by Encompass to the Company on a temporary basis under the TSA. The TSA expired under its terms on March 31, 2024.

Data Analytics Investment

During 2019, the Company made a $2.0 million investment in Medalogix, LLC (“Medalogix”), a healthcare predictive data and analytics company. During 2021, Medalogix became a wholly-owned subsidiary of TVG Holdings, LLC (“TVG”), which resulted in the Company obtaining a minority equity investment in TVG in exchange for its investment in Medalogix. This investment was accounted for under the measurement alternative for investments.

On March 19, 2025 (the “Transaction Date”), Medalogix was combined with Forcura in a private equity-backed transaction (the “Transaction”). In connection with the Transaction, the Company sold its investment interest in TVG for approximately $21 million. The Transaction resulted in the Company recording a gain on sale of investment of approximately $19.3 million in Other (income) expenses on the unaudited Condensed Consolidated Statement of Income. On March 31, 2025, the Company used $20.0 million of the proceeds from the Transaction to reduce debt under the Credit Agreement. See also Note 3, Long‑Term Debt. The costs incurred during the nine months ended September 30, 2025, disclosed in the paragraph below, include only payments made to Medalogix prior to the Transaction Date.

As of the Transaction Date, Medalogix was no longer a related party of the Company. Costs incurred prior to the Transaction Date were approximately $1.2 million for the nine months ended September 30, 2025, and $1.2 million and $3.6 million for the three and nine months ended September 30, 2024, respectively, in connection with the usage of Medalogix’s analytics platforms while Medalogix was a related party. These costs are included in Cost of service, excluding depreciation and amortization, and General and administrative expenses in the unaudited Condensed Consolidated Statements of Income.

9.Supplemental Cash Flow Information

The following table provides supplemental cash flow information and disclosures of non-cash investing and financing activities for the nine months ended September 30, 2025 and 2024 (in millions):


	Nine Months Ended September 30,
	2025		2024
Supplemental cash flow disclosures:
Cash paid (refunds received) for income taxes, net	$	0.6	$	(0.6)
Cash paid for interest	$	25.3	$	33.1
Supplemental cash flow disclosures of non-cash investing and financing activities:

Property and equipment additions through finance leases	$	0.1	$	5.4
Operating lease additions	$	9.6	$	8.6

The following table details supplemental cash flow disclosures related to the reconciliation of cash and cash equivalents and restricted cash balances (in millions):


	As of September 30, 2025		As of December 31, 2024
Cash, cash equivalents, and restricted cash reconciliation:
Cash and cash equivalents	$	56.9	$	28.4
Restricted cash	2.0		1.9
Cash, cash equivalents, and restricted cash at end of period	$	58.9	$	30.3

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless specified otherwise, references to “we,” “us,” “our,” the “Company,” or “Enhabit” hereafter refer to Enhabit, Inc. and its subsidiaries. You should read the following discussion and analysis together with our unaudited condensed consolidated financial statements and related notes included under Part I, Item 1, “Financial Statements (Unaudited),” of this report. Among other things, those historical financial statements include more detailed information regarding the basis of presentation for the financial data included in the following discussion. This discussion contains forward-looking statements about our business, operations and industry that involve risks and uncertainties, as described under the section titled “Cautionary Note Regarding Forward-Looking Statements.”

Overview

We are a leading provider of home health and hospice services in the United States. We strive to provide superior, cost-effective care where patients prefer it: in their homes. For over twenty-five years, we have provided care in the low‑cost home setting while achieving high-quality clinical outcomes. As of September 30, 2025, our footprint comprised 247 home health and 115 hospice locations across 34 states.

Our operations are principally managed on a services basis and include two operating segments for financial reporting purposes: (i) Home Health and (ii) Hospice. For additional information about our business and reportable segments, see Item 1, “Business,” and Item 1A, “Risk Factors,” in the Company’s Annual Report for the year ended December 31, 2024 on Form 10-K (the “Form 10-K”) filed with the United States Securities and Exchange Commission (the “SEC”) on March 6, 2025 and Note 7, Segment Reporting, to the accompanying unaudited condensed consolidated financial statements, and “—Segment Results of Operations” section of this item.

Recent Developments

Branch Closures

During the three months ended September 30, 2025, the Company consolidated a Home Health branch and a Hospice branch, bringing the total number of branches closed or consolidated during 2025 to 13—eight Home Health branches and five Hospice branches. We will continue to analyze financial performance at the branch level, but we do not anticipate additional branch closures or consolidation for the remainder of 2025.

Factors Affecting Our Performance

There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth. These factors include:

Pricing

Generally, the pricing we receive for our services is based on reimbursement rates from payers. Because we derive a substantial portion of our Net service revenue from the Medicare program, our results of operations are heavily impacted by changes in Medicare reimbursement rates. Medicare reimbursement rates are subject to change annually.

On August 1, 2025, the Centers for Medicare and Medicaid Services (“CMS”) issued its final rule for hospice payments for fiscal year 2026 (the “2026 Hospice Final Rule”). Effective October 1, 2025, CMS will implement a net increase of 2.6% to payments as compared to 2025 payments. This update represents a 3.3% update to the market basket, reduced by a 0.7% productivity adjustment. Based on our analysis of the 2026 Hospice Final Rule, we expect the impact to us to be in line with the 2.6% increase for services provided beginning October 1, 2025.

On June 30, 2025, CMS issued its proposed rule for home health payments for fiscal year 2026 (the “2026 Home Health Rule”). CMS proposed a 6.4% estimated decrease to payments as compared to 2025 payments. This update represents a 2.4% increase to the market basket, reduced by a 3.7% decrease that reflects the net impact of the proposed permanent behavior adjustment, a 4.6% decrease that reflects the net impact of the proposed temporary adjustment, and an estimated decrease of 0.5% that reflects the effects of a proposed update to the fixed-dollar loss ratio.

The final 2026 Home Health Rule, when released, will be effective for services provided beginning January 1, 2026. Based on our analysis of the proposed 2026 Home Health Rule, we expect the impact to us to be in line with the 6.4% decrease, if implemented as proposed. We are actively engaged in advocacy efforts in response to the proposed 2026 Home

Table of Contents

Health Rule, which, if finalized as proposed, could result in a significant reduction in reimbursement rates for our industry. As the ultimate impact of the proposed 2026 Home Health Rule remains uncertain, we continue to monitor developments.

For further discussion of other pricing factors that impact our results of operations and growth, see Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” in the Form 10-K.

Efficiency

Cost and operating efficiencies impact the profitability of the patient care services we provide. We use a number of strategies to drive cost and operating efficiencies within our business. In addition, due to the severity of the proposed cuts in the 2026 Home Health Rule, management is evaluating additional options for further cost control and operating efficiencies, including, among other things, advanced clinically based management of visits per episode (“VPE”). During the third quarter, we implemented a VPE management pilot program for a subset of Home Health branches, and based on early results of that pilot program we anticipate deploying it to all Home Health branches during the fourth quarter.

For further discussion of cost and operating efficiency strategies, see Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” in the Form 10-K.

Impact of Inflation

Inflation has impacted us primarily with respect to our labor costs. The healthcare industry is labor intensive, and wages and other expenses may increase during periods of inflation or when labor shortages occur in the marketplace. For further discussion of inflation’s impact to cost control measures, see Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” in the Form 10-K.

Recruiting and Retaining High-Quality Personnel

Recruiting and retaining qualified personnel, including management, for our home health agencies and hospice provider locations remains a high priority for us. We attempt to maintain a comprehensive compensation and benefits package to compete in the current challenging staffing environment.

Table of Contents

Results of Operations

Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements included in the Form 10-K.

Our consolidated results of operations were as follows:


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
(in millions, except percentages)	2025		2024		2025 vs. 2024		2025		2024		2025 vs. 2024
Net service revenue	$	263.6	$	253.6	3.9	%	$	789.6	$	776.6	1.7	%
Cost of service, excluding depreciation and amortization	135.8		131.7		3.1	%	401.5		397.7		1.0	%
Gross margin, excluding depreciation and amortization	127.8		121.9		4.8	%	388.1		378.9		2.4	%
General and administrative expenses	105.5		103.8		1.6	%	321.2		321.3		—	%
Depreciation and amortization	5.5		8.2		(32.9)	%	17.5		23.6		(25.8)	%
Impairment of goodwill	—		107.9		N/A		—		107.9		N/A
Operating income (loss)	16.8		(98.0)		117.1	%	49.4		(73.9)		166.8	%
Interest expense and amortization of debt discounts and fees	8.3		10.8		(23.1)	%	26.4		32.8		(19.5)	%

Other (income) expenses	0.1		—		N/A		(19.2)		—		N/A
Income (loss) before income taxes and noncontrolling interests	8.4		(108.8)		107.7	%	42.2		(106.7)		139.6	%
(Benefit from) provision for income taxes	(3.2)		0.7		557.1	%	6.5		1.5		333.3	%
Net income (loss)	11.6		(109.5)		110.6	%	35.7		(108.2)		133.0	%
Less: Net income attributable to noncontrolling interests	0.5		0.7		(28.6)	%	1.6		2.0		(20.0)	%
Net income (loss) attributable to Enhabit, Inc.	$	11.1	$	(110.2)	110.1	%	$	34.1	$	(110.2)	130.9	%

The following table sets forth our consolidated results as a percentage of Net service revenue:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Cost of service, excluding depreciation and amortization	51.5	%	51.9	%	50.8	%	51.2	%
General and administrative expenses	40.0	%	40.9	%	40.7	%	41.4	%
Depreciation and amortization	2.1	%	3.2	%	2.2	%	3.0	%

Net Service Revenue. For the three months ended September 30, 2025, Net service revenue increased 3.9% compared to the prior period due to increased Hospice segment revenue of 20.0% partially offset by a decrease in Home Health segment revenue of 0.2%. See “—Segment Results of Operations.”

For the nine months ended September 30, 2025, Net service revenue increased 1.7% compared to the prior period due to increased Hospice segment revenue of 20.0% partially offset by a decrease in Home Health segment revenue of 2.8%. See “—Segment Results of Operations.”

Cost of Service, Excluding Depreciation and Amortization. For the three months ended September 30, 2025, Cost of service, excluding depreciation and amortization increased 3.1% compared to the prior period. This increase resulted from an increase in the Hospice segment, Cost of service, excluding depreciation and amortization of 8.9% and an increase in Home Health segment, Cost of service, excluding depreciation and amortization expense of 1.7%.

For the nine months ended September 30, 2025, Cost of service, excluding depreciation and amortization increased 1.0% compared to the prior period. This increase resulted from an increase in the Hospice segment, Cost of service, excluding depreciation and amortization of 10.9% partially offset by a decrease in the Home Health segment, Cost of service, excluding depreciation and amortization of 1.4%.

See “—Segment Results of Operations.”

General and Administrative Expenses. For the three months ended September 30, 2025, General and administrative expenses increased compared to the same period in the prior year, primarily attributable to an increase in estimated incentive compensation partially offset by cost control initiatives.

For the nine months ended September 30, 2025, General and administrative expenses remained relatively flat compared to the same period in the prior year.

Depreciation and Amortization. For the three and nine months ended September 30, 2025, Depreciation and amortization decreased compared to the same periods of 2024 due to a number of intangible assets, including licenses and non-compete agreements, reaching the end of their useful lives in 2024.

Interest Expense and Amortization of Debt Discounts and Fees. For the three and nine months ended September 30, 2025, Interest expense and amortization of debt discounts and fees decreased compared to the same periods of 2024 primarily due to a lower average borrowing level under our credit facilities and lower average interest rates. See additional discussion on Note 3, Long‑Term Debt, to the accompanying unaudited condensed consolidated financial statements and “—Liquidity and Capital Resources” within this item.

Other (Income) Expenses. For the nine months ended September 30, 2025, Other (income) expenses consisted primarily of a gain on sale of investment. See additional discussion in Note 8, Related Party Transactions, to the accompanying unaudited condensed consolidated financial statements.

(Benefit From) Provision for Income Taxes. Our effective income tax rates were (38.1)% and (0.6)% for the three months ended September 30, 2025 and 2024, respectively. Our effective income tax rates were 15.4% and (1.4)% for the nine months ended September 30, 2025 and 2024, respectively. The differences in the 2025 rates as compared to the 2024 rates are primarily due to unfavorable permanent differences attributable to the impairment of goodwill in the third quarter of 2024, a valuation allowance recorded in the third quarter of 2024, and a reduction to the valuation allowance recorded in the third quarter of 2025. See additional discussion in Note 4, Income Taxes, to the accompanying unaudited condensed consolidated financial statements.

Adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure of our financial performance. Management believes Adjusted EBITDA assists investors in comparing our operating performance across operating periods on a consistent basis by excluding items we do not believe are indicative of our operating performance.

We calculate Adjusted EBITDA as Net income (loss) adjusted to exclude (i) interest expense and amortization of debt discounts and fees, (ii) provision for (benefit from) income taxes, (iii) depreciation and amortization, (iv) gains or losses on disposal or impairment of assets, investments, or goodwill, (v) stock‑based compensation, (vi) net income attributable to noncontrolling interests and (vii) unusual or nonrecurring items not typical of ongoing operations.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for Net income (loss). Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the accompanying unaudited condensed consolidated financial statements.

The following table reconciles Net income (loss) to Adjusted EBITDA (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net income (loss)	$	11.6	$	(109.5)	$	35.7	$	(108.2)
Interest expense and amortization of debt discounts and fees	8.3		10.8		26.4		32.8
(Benefit from) provision for income taxes	(3.2)		0.7		6.5		1.5
Depreciation and amortization	5.5		8.2		17.5		23.6
Loss (gain) on sale of investment and disposal of assets	0.1		(0.3)		(19.2)		(0.5)
Impairment of goodwill	—		107.9		—		107.9
Stock-based compensation	2.2		3.8		9.8		7.8
Net income attributable to noncontrolling interests	(0.5)		(0.7)		(1.6)		(2.0)
Unusual or nonrecurring items that are not typical of ongoing operations	3.0		3.6		5.4		12.1


Adjusted EBITDA	$	27.0	$	24.5	$	80.5	$	75.0

Unusual or nonrecurring items in the three months ended September 30, 2025 include: (i) restructuring activities and severance costs; (ii) third-party legal fees associated with the suit Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. and pending in the Chancery Court of Delaware, and in which the Company has asserted claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers; and (iii) third-party legal and advisory fees related to non-shareholder matters. The nine months ended September 30, 2025 include: (i) restructuring activities and severance costs; (ii) third-party legal fees associated with the Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. lawsuit referenced above; and (iii) third-party legal and advisory fees related to shareholder and non-shareholder matters. The three months ended September 30, 2024 include: (i) third-party legal and advisory fees related to shareholder activism and (ii) restructuring activities and severance costs. The nine months ended September 30, 2024 include: (i) third-party legal and advisory fees related to shareholder activism; (ii) third‑party legal and advisory fees related to the strategic review process that concluded in May 2024; and (iii) certain third-party legal fees associated with the Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. lawsuit referenced above.

For additional information, see “—Segment Results of Operations.”

Segment Results of Operations

Our segment and consolidated Net service revenue is provided in the following tables:


	Three Months Ended September 30,
	2025			2024
(in millions, except percentages)	$ Amount		% of Consolidated Revenue	$ Amount		% of Consolidated Revenue
Home Health segment net service revenue	$	200.5	76.1 %	$	201.0	79.3 %
Hospice segment net service revenue	63.1		23.9 %	52.6		20.7 %
Consolidated net service revenue	$	263.6	100.0 %	$	253.6	100.0 %

	Nine Months Ended September 30,
	2025			2024
(in millions, except percentages)	$ Amount		% of Consolidated Revenue	$ Amount		% of Consolidated Revenue
Home Health segment net service revenue	$	607.0	76.9 %	$	624.4	80.4 %
Hospice segment net service revenue	182.6		23.1 %	152.2		19.6 %
Consolidated net service revenue	$	789.6	100.0 %	$	776.6	100.0 %

Table of Contents

For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of Segment Adjusted EBITDA to Income (loss) before income taxes and noncontrolling interests, see Note 7, Segment Reporting, to the accompanying unaudited condensed consolidated financial statements.

Home Health

Our Home Health segment derived its Net service revenue from the following payer sources:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Medicare	56.6	%	58.4	%	56.6	%	58.9	%
Medicare Advantage	30.5	%	29.5	%	30.6	%	28.8	%
Managed Care	11.7	%	11.0	%	11.3	%	11.0	%
Medicaid	0.8	%	1.1	%	0.9	%	1.1	%
Other	0.4	%	—	%	0.6	%	0.2	%
Total	100.0	%	100.0	%	100.0	%	100.0	%

See Item 1, “Business,” in the Form 10-K for additional information on our payer mix.

Additional information regarding our Home Health segment’s operating results is as follows:


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
(in millions, except percentages)	2025		2024		2025 vs. 2024		2025		2024		2025 vs. 2024
Net service revenue:
Medicare	$	113.4	$	117.3	(3.3)	%	$	343.6	$	367.3	(6.5)	%
Non-Medicare	85.2		81.5		4.5	%	257.4		250.5		2.8	%
Private duty(1)	1.9		2.2		(13.6)	%	6.0		6.6		(9.1)	%
Home Health net service revenue	200.5		201.0		(0.2)	%	607.0		624.4		(2.8)	%
Cost of service, excluding depreciation and amortization	107.7		105.9		1.7	%	318.3		322.7		(1.4)	%
Gross margin, excluding depreciation and amortization	92.8		95.1		(2.4)	%	288.7		301.7		(4.3)	%
General and administrative expenses	58.5		58.2		0.5	%	176.0		176.3		(0.2)	%

Net income attributable to noncontrolling interests	0.4		0.4		—	%	1.2		1.5		(20.0)	%
Home Health Segment Adjusted EBITDA(2)	$	33.9	$	36.5	(7.1)	%	$	111.5	$	123.9	(10.0)	%

(1) Private duty represents long-term comprehensive hourly nursing medical care.

(2) Segment Adjusted EBITDA is presented in conformity with ASC 280, Segment Reporting, as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments. Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance. For more information, see Note 7, Segment Reporting, to the unaudited condensed consolidated financial statements.

Table of Contents


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
(actual amounts)	2025		2024		2025 vs. 2024		2025		2024		2025 vs. 2024
Medicare:
Admissions	22,225		23,422		(5.1)	%	69,407		73,381		(5.4)	%
Recertifications	15,890		16,101		(1.3)	%	47,484		50,392		(5.8)	%
Completed episodes	37,875		38,866		(2.5)	%	114,959		123,657		(7.0)	%
Average daily census	19,361		19,629		(1.4)	%	19,798		20,652		(4.1)	%
Visits	530,078		561,525		(5.6)	%	1,624,645		1,791,314		(9.3)	%
Visits per episode	14.0		14.4		(2.8)	%	14.1		14.5		(2.8)	%
Revenue per episode	$	2,994	$	3,018	(0.8)	%	$	2,989	$	2,970	0.6	%
Non-Medicare:
Admissions	33,065		29,950		10.4	%	98,017		91,040		7.7	%
Recertifications	14,410		14,112		2.1	%	42,075		42,188		(0.3)	%
Average daily census	22,090		20,358		8.5	%	21,806		20,726		5.2	%
Visits	562,122		552,815		1.7	%	1,675,072		1,705,430		(1.8)	%
Total:
Admissions	55,290		53,372		3.6	%	167,424		164,421		1.8	%

Recertifications	30,300		30,213		0.3	%	89,559		92,580		(3.3)	%

Average daily census	41,451		39,987		3.7	%	41,604		41,378		0.5	%
Visits	1,092,200		1,114,340		(2.0)	%	3,299,717		3,496,744		(5.6)	%
Visits per episode	13.4		14.1		(5.0)	%	13.7		14.4		(4.9)	%
Cost per visit	$	97.4	$	94.0	3.6	%	$	95.2	$	90.9	4.7	%
Revenue per patient day	$	52.6	$	54.6	(3.7)	%	$	53.4	$	55.1	(3.1)	%
Cost per patient day	$	28.2	$	28.8	(2.1)	%	$	28.0	$	28.5	(1.8)	%

Expenses as a Percentage of Net Service Revenue


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Cost of service, excluding depreciation and amortization	53.7	%	52.7	%	52.4	%	51.7	%
General and administrative expenses	29.2	%	29.0	%	29.0	%	28.2	%

Net Service Revenue. For the three months ended September 30, 2025, Home Health Net service revenue decreased 0.2% compared to the same period of 2024 due to a decrease in unit revenue per patient day of 3.7%, primarily related to growth in our non-Medicare patients, partially offset by an increase in average daily census of 3.7%.

For the nine months ended September 30, 2025, Home Health Net service revenue decreased 2.8% compared to the same period of 2024 due to a decrease in unit revenue per patient day of 3.1% primarily related to growth in our non‑Medicare patients, partially offset by an increase in average daily census of 0.5%.

Segment Adjusted EBITDA. The decrease in Segment Adjusted EBITDA of 7.1% during the three months ended September 30, 2025 compared to the same period of 2024 primarily was the result of an increase in Cost of service, excluding depreciation and amortization of 1.7% with cost per patient day decreasing 2.1% partially offset by an increase in average daily census of 3.7%. The decrease in average daily census was primarily related to on-going payer contract renegotiation during the early part of the quarter with a national payer, which were resolved by September 30, 2025.

The decrease in Home Health Segment Adjusted EBITDA of 10.0% during the nine months ended September 30, 2025 compared to the same period of 2024 resulted primarily from the decrease in Net service revenue of 2.8%, as discussed above, partially offset by decreased Cost of service, excluding depreciation and amortization of 1.4% attributable to improved clinical staff productivity in 2025.

Table of Contents

Hospice

Our Hospice segment derived its Net service revenue from the following payer sources:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Medicare	99.8	%	98.3	%	98.6	%	98.6	%

Managed Care	0.2	%	0.6	%	1.0	%	1.4	%
Medicaid	—	%	1.1	%	0.4	%	—	%

Total	100.0	%	100.0	%	100.0	%	100.0	%

Additional information regarding our Hospice segment’s operating results is as follows:


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
(in millions, except percentages)	2025		2024		2025 vs. 2024		2025		2024		2025 vs. 2024
Hospice net service revenue	$	63.1	$	52.6	20.0	%	$	182.6	$	152.2	20.0	%
Cost of service, excluding depreciation and amortization	28.1		25.8		8.9	%	83.2		75.0		10.9	%
Gross margin, excluding depreciation and amortization	35.0		26.8		30.6	%	99.4		77.2		28.8	%
General and administrative expenses	17.7		16.5		7.3	%	52.8		48.5		8.9	%

Net income attributable to noncontrolling interests	0.1		0.3		(66.7)	%	0.4		0.5		(20.0)	%
Hospice Segment Adjusted EBITDA(1)	$	17.2	$	10.0	72.0	%	$	46.2	$	28.2	63.8	%



(actual amounts)
Total:
Admissions	3,089		3,046		1.4	%	9,503		8,966		6.0	%

Patient days	375,039		333,247		12.5	%	1,077,309		961,815		12.0	%
Discharged average length of stay	101		100		1.0	%	102		104		(1.9)	%
Average daily census	4,077		3,622		12.6	%	3,946		3,510		12.4	%
Revenue per patient day	$	168.2	$	157.7	6.7	%	$	169.5	$	158.2	7.1	%
Cost per patient day	$	74.9	$	77.3	(3.1)	%	$	77.2	$	78.0	(1.0)	%

(1) Segment Adjusted EBITDA is presented in conformity with ASC 280, Segment Reporting, as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments. Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance. For more information, see Note 7, Segment Reporting, to the unaudited condensed consolidated financial statements.

Expenses as a Percentage of Net Service Revenue


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Cost of service, excluding depreciation and amortization	44.5	%	49.0	%	45.6	%	49.3	%
General and administrative expenses	28.1	%	31.4	%	28.9	%	31.9	%

Net Service Revenue. For the three months ended September 30, 2025, Hospice Net service revenue increased 20.0% compared to the same period of 2024 due to an increase in average daily census of 12.6%, as we continue to see the benefits of our maturing case management model, and improved unit revenue per patient day of 6.7% due primarily to

Table of Contents

improved Medicare reimbursement rates, compared to the same period in 2024, in the three months ended September 30, 2025.

For the nine months ended September 30, 2025, Hospice Net service revenue increased 20.0% compared to the same period of 2024 due to an increase in average daily census of 12.4%, as we continue to see the benefits of our maturing case management model, and improved unit revenue per patient day of 7.1% due primarily to improved Medicare reimbursement rates, compared to the same period in 2024.

Segment Adjusted EBITDA. The increase in Hospice Segment Adjusted EBITDA of 72.0% during the three months ended September 30, 2025 compared to the same period of 2024 resulted primarily from the increase in Net service revenue of 20.0%, as discussed above, with Cost of service, excluding depreciation and amortization, higher by 8.9% to support revenue growth, partially offset by improved clinical staff productivity with a decrease in cost per patient day of 3.1%. Hospice General and administrative expenses increased 7.3% due to increased selling-related and back-office support expenses to support revenue growth.

The increase in Hospice Segment Adjusted EBITDA of 63.8% during the nine months ended September 30, 2025 compared to the same period of 2024 resulted primarily from the increase in Net service revenue of 20.0%, as discussed above, with Cost of service, excluding depreciation and amortization, higher by 10.9% to support revenue growth, partially offset by improved clinical staff productivity with a decrease in cost per patient day of 1.0%. Hospice General and administrative expenses increased 8.9% due to increased selling‑related and back-office support expenses to support revenue growth.

Liquidity and Capital Resources

Our principal sources of short-term liquidity are our cash on hand and our revolving credit facility. We use these sources to fund working capital requirements, capital expenditures and acquisitions, and to service our debt. See “—Contractual Obligations” for more information about our material cash requirements from our contractual obligations at September 30, 2025.

As of September 30, 2025 and December 31, 2024, we had $56.9 million and $28.4 million, respectively, in Cash and cash equivalents. These amounts exclude $2.0 million and $1.9 million, respectively, in Restricted cash. Our Restricted cash pertains primarily to a joint venture in which our joint venture partner requested, and we agreed, the joint venture’s cash not be commingled with other corporate cash accounts. See Note 1, Summary of Significant Accounting Policies—Cash and Cash Equivalents and —Restricted Cash, to the consolidated financial statements included in the Form 10-K. As of September 30, 2025, we also had $86.4 million available to us under the Revolving Credit Facility.

On March 19, 2025, Medalogix was combined with Forcura in a private equity-backed transaction (the “Transaction”). In connection with the Transaction, we sold our investment interest in TVG Holdings, LLC (“TVG”) for approximately $21 million. On March 31, 2025, we used $20.0 million of the proceeds from the Transaction to reduce debt under our Credit Agreement. We expect to incur approximately $3.3 million of cash tax liability from the sale, of which a portion is payable in future periods.

For additional information regarding our debt, see Note 3, Long‑Term Debt, to the accompanying unaudited condensed consolidated financial statements and Item 3, “Quantitative and Qualitative Disclosures About Market Risk.”

The following table shows the cash flows provided by or used in operating, investing, and financing activities (in millions):


	Nine Months Ended September 30,
	2025		2024
Net cash provided by operating activities	$	66.3	$	55.3
Net cash provided by (used in) investing activities	17.6		(2.1)
Net cash used in financing activities	(55.3)		(35.6)
Increase in cash, cash equivalents, and restricted cash	$	28.6	$	17.6

Operating Activities. The increase in Net cash provided by operating activities during the nine months ended September 30, 2025 as compared to 2024 primarily resulted from increased net income and changes in working capital.

Table of Contents

Investing Activities. During the nine months ended September 30, 2025, Net cash provided by investing activities primarily resulted from the proceeds from the sale of an investment. During the nine months ended September 30, 2024, Net cash used in investing activities primarily resulted from purchases of property and equipment.

Financing Activities. During the nine months ended September 30, 2025 and 2024, Net cash used in financing activities primarily resulted from repayments of borrowings under our term loan facility and prepayments of borrowings under our revolving credit facility.

Contractual Obligations

Our consolidated contractual obligations as of September 30, 2025 are as follows (in millions):


	Total		Current		Long-Term
Long-term debt obligations:
Long-term debt, excluding revolving credit facility, finance lease obligations and unamortized debt issuance costs	$	335.0	$	20.0	$	315.0
Revolving credit facility	125.0		—		125.0
Interest on long-term debt(1)	86.1		28.7		57.4
Finance lease obligations(2)	5.6		2.6		3.0
Operating lease obligations(3)	63.4		15.9		47.5
Purchase obligations(4)	45.3		23.6		21.7
Total	$	660.4	$	90.8	$	569.6

(1)Interest on long-term debt was calculated using the rate for the Term Loan A Facility as of September 30, 2025.

(2)We lease automobiles for our clinicians under finance leases. Amounts include the interest portion of future minimum finance lease payments. For more information, see Note 6, Leases, to the consolidated financial statements included in the Form 10-K.

(3)In addition to our corporate headquarters office space, our Home Health and Hospice segments lease: (i) relatively small office spaces in the localities they serve; and (ii) equipment in the normal course of business. Amounts include the interest portion of future minimum operating lease payments. For more information, see Note 6, Leases, to the consolidated financial statements included in the Form 10-K.

(4)Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support. Purchase obligations are not recognized in our unaudited Condensed Consolidated Balance Sheet. For more information, see Note 6, Contingencies and Other Commitments, to the accompanying unaudited condensed consolidated financial statements.

Our capital expenditures include costs associated with computer hardware and licensing software we utilize to run our business, as well as leasehold improvements. During 2025, we expect to spend approximately between $4 to $5 million for maintenance capital expenditures. During the nine months ended September 30, 2025 and 2024, we made capital expenditures of $3.8 million and $3.2 million, respectively, for property and equipment and capitalized software.

Critical Accounting Estimates

There have been no material changes to our critical accounting estimates from those disclosed in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates,” in the Form 10‑K.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use sensitivity analysis models to evaluate the impact of interest rate changes on our variable rate debt. As of September 30, 2025, our primary variable rate debt outstanding related to $125.0 million in advances under our Revolving Credit Facility and $335.0 million under our Term Loan A Facility.

On October 20, 2022, we entered into an interest rate swap. The interest rate swap had a $200.0 million notional value and a maturity date of October 20, 2025. Beginning in October 2022, we received the one-month SOFR and paid a fixed rate of interest of 4.3%. The impact of increases and decreases in interest rates on our cash flow discussed below includes the impact of the interest rate swap.

Assuming outstanding balances were to remain the same, a 1% increase in interest rates would result in an incremental negative cash flow of $2.6 million over the next 12 months, while a 1% decrease in interest rates would result in an incremental positive cash flow of $2.6 million over the next 12 months.

See Note 3, Long‑Term Debt, to the accompanying unaudited condensed consolidated financial statements for additional information regarding our long-term debt.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. Based on the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended September 30, 2025 in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. Some of these matters have been material to us in the past, and others in the future may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity. We do not believe any of our pending legal proceedings are material to us, but there can be no assurance our assessment will not change based on future developments.

Additionally, the False Claims Act (the “FCA”) allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as “qui tam” actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed qui tam cases brought pursuant to the FCA.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed in Item 1A, “Risk Factors,” in the Form 10-K for the period ended December 31, 2024.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

During the three months ended September 30, 2025, we purchased shares of our common stock as follows:


	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans	Approximate Dollar Value of Shares That May Yet Be Purchased Under Our Share Repurchase Plans
July 1 through July 31	32,706	$	7.88	—	—
August 1 through August 31	1,224	7.80		—	—
September 1 through September 30	—	—		—	—
Total	33,930	$	7.88	—	—

(1)Represents shares of common stock we repurchased to satisfy employee tax-withholding obligations in connection with the vesting of stock‑based compensation awards.

ITEM 5. OTHER INFORMATION

None of the Company’s directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended September 30, 2025.

ITEM 6. EXHIBITS

EXHIBIT INDEX

Exhibit

Number

Exhibit Description

2.1

Separation and Distribution Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.1 to Enhabit, Inc.’s Current Report on Form 8-K filed on July 5, 2022).

3.1

Amended and Restated Certificate of Incorporation of Enhabit, Inc. (incorporated by reference to Exhibit 3.1.2 to Enhabit, Inc.’s Current Report on Form 8-K filed on July 5, 2022).

3.2

Amended and Restated Bylaws of Enhabit, Inc. (incorporated by reference to Exhibit 3.2 to Enhabit, Inc.’s Quarterly Report on Form 10-Q for the three months ended September 30, 2022).

10.1*

Transition, Separation and Release Agreement between Advanced Homecare Management, LLC d/b/a Enhabit Home Health & Hospice and Barbara A. Jacobsmeyer, dated August 5, 2025 (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.’s Current Report on Form 8-K filed on August 6, 2025).

10.2*

Form of Restricted Stock Units Agreement (Special Retention Grant), pursuant to the 2025 Enhabit, Inc. Equity and Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to Enhabit, Inc.’s Current Report on Form 8-K filed on August 6, 2025).

10.3*

Form of Cash Retention Bonus Letter Agreement (Executive Officers) (incorporated by reference to Exhibit 10.3 to Enhabit, Inc.’s Current Report on Form 8-K filed on August 6, 2025).

31.1†

Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†

Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1+

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2+

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS†

XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

101.SCH†

Inline XBRL Taxonomy Extension Schema Document.

101.CAL†

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF†

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB†

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE†

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104†

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

† Filed herewith as an exhibit.

+ Furnished herewith as an exhibit.

* Indicates management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			ENHABIT, INC.

			By:			/s/ Ryan Solomon
						Ryan Solomon
						Chief Financial Officer

			Date:			November 5, 2025

Enhabit, Inc. 10-Q